Page last updated: 2024-12-06

sennoside A

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sennoside A is a naturally occurring anthraquinone glycoside found in the leaves of the Senna plant. It is a potent stimulant laxative that works by increasing water and electrolyte secretion in the colon, leading to increased bowel movements. Sennoside A is also a known inhibitor of certain cancer cell lines, and studies are ongoing to explore its potential as a therapeutic agent in cancer treatment. Due to its pharmacological activity and potential therapeutic uses, sennoside A has been a subject of extensive research.'

sennoside A : A member of the class of sennosides that is rel-(9R,9'R)-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid which is substituted by hydroxy groups at positions 4 and 4', by beta-D-glucopyranosyloxy groups at positions 5 and 5', and by oxo groups at positions 10 and 10'. The exact stereochemisty at positions 9 and 9' is not known - it may be R,R (as shown) or S,S. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Sennagenus[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID73111
CHEMBL ID2368547
CHEBI ID9112
SCHEMBL ID440792

Synonyms (71)

Synonym
nsc112929
nsc-112929
(9r,9'r)-5,5'-bis(beta-d-glucopyranosyloxy)-4,4'-dihydroxy-10,10'-dioxo-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid
ccris 7489
sennae folium
senokot
8013-11-4
MEGXP0_001902
senna
ACON0_001464
SMP1_000271
81-27-6
sennoside a
NCGC00095095-01
einecs 201-339-9
nsc 112929
senna (powdered)
LMPK13040016
[9,9' -bianthracene] -2,2' -dicarboxylic acid, 5,5' -bis(.beta. -d-glucopyranosyloxy) -9,9' ,10,10' -tetrahydro-4,4' - dihydroxy-10,10' -dioxo-, (r*,r*) - (9ci)
(9r)-9-[(9r)-2-carboxy-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-9h-anthracene-2-carbo
AC-6075
(9r)-9-[(9r)-2-carboxy-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid
niosh/vt6020000
sennosides a + b 99%
VT60200000
gentlax
sennalax
dosaflex
senolax
black draught
chebi:9112 ,
CHEMBL2368547
tox21_111420
dtxsid1023576 ,
cas-81-27-6
dtxcid803576
AKOS015960468
2f1o30gvxh ,
unii-2f1o30gvxh
bdbm92481
sennoside a, g
85085-71-8
(r*,r*)-5,5'-bis(.beta.-d-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo(9,9'-bianthracene)-2,2'-dicarboxylic acid
sennosides sennoside a [mi]
sennoside a (constituent of senna leaf and pods) [dsc]
(9,9'-bianthracene)-2,2'-dicarboxylic acid, 5,5'-bis(.beta.-d-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo-, (9r,9'r)-
(9r,9r)-5,5-bis(.beta.-d-glucopyranosyloxy)-9,9,10,10-tetrahydro-4,4-dihydroxy-10,10-dioxo(9,9-bianthracene)-2,2-dicarboxylic acid
sennoside a [who-dd]
sennoside a [usp-rs]
SCHEMBL440792
(9r*,9'r*)-5,5'-bis(beta-d-glucopyranosyloxy)-4,4'-dihydroxy-10,10'-dioxo-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid
(-)-(9r*,9'r*)-5,5'-bis(beta-d-glucopyranosyloxy)-4,4'-dihydroxy-10,10'-dioxo-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid
Q-201704
mfcd00151527
senan
exprep
amyran
moivat
glaxenna
tisasen a
(9r,9'r)-4,4'-dihydroxy-10,10'-dioxo-5,5'-bis((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid
S4033
(9r,9'r)-4,4'-dihydroxy-10,10'-dioxo-5,5'-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})-9h,9'h,10h,10'h-[9,9'-bianthracene]-2,2'-dicarboxylic acid
AS-75207
Q27108275
HMS3885E20
CCG-270540
NCGC00385183-01
(9r,9'r)-4,4'-dihydroxy-10,10'-dioxo-5,5'-bis(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-9,9',10,10'-tetrahydro-[9,9'-bianthracene]-2,2'-dicarboxylic acid
(9r,9's)-4,4'-dihydroxy-10,10'-dioxo-5,5'-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})-9h,9'h,10h,10'h-[9,9'-bianthracene]-2,2'-dicarboxylic acid
AS-80195

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (7 Product(s))

Product Categories

Product CategoryProducts
Food & Beverages1
Beauty & Personal Care6

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Hobe Labs Ultra Slim Tea Cran-Raspberry -- 24 Tea BagsHobe LabsFood & Beverages Senna2024-11-29 10:47:42
Light Mountain Color The Gray Light Brown -- 7 fl ozLight MountainBeauty & Personal Caresenna2024-11-29 10:47:42
Light Mountain Color The Gray! Medium Brown -- 7 ozLight MountainBeauty & Personal CareSenna2024-11-29 10:47:42
Light Mountain Natural Hair Color and Conditioner Auburn -- 4 fl ozLight MountainBeauty & Personal Careindigo, henna, senna2024-11-29 10:47:42
Light Mountain Natural Hair Color and Conditioner Light Brown -- 4 fl ozLight MountainBeauty & Personal Careindigo, henna, senna2024-11-29 10:47:42
Light Mountain Natural Hair Color and Conditioner Light Red® -- 4 fl ozLight MountainBeauty & Personal Carehenna, senna2024-11-29 10:47:42
Light Mountain Natural Hair Color and Conditioner Medium Brown -- 4 fl ozLight MountainBeauty & Personal Careindigo, henna, senna2024-11-29 10:47:42

Drug Classes (2)

ClassDescription
sennosidesA class of beta-D-glucosides of reductively-coupled dimers of hydroxyanthraquinones found particularly in senna (Cassia augustifolia) and rhubarb (Rheum rhabarbarum).
oxo dicarboxylic acidAny dicarboxylic acid carrying one or more oxo groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.39810.003245.467312,589.2998AID2517
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency7.94330.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)10.00000.00403.43889.5100AID1640022
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)51.00000.03703.385910.0000AID1799783
Tissue-type plasminogen activatorHomo sapiens (human)IC50 (µMol)51.00000.03402.54256.6000AID1799783
Plasminogen activator inhibitor 1Homo sapiens (human)IC50 (µMol)51.00000.09104.892810.0000AID1799783
Urokinase-type plasminogen activatorMus musculus (house mouse)IC50 (µMol)51.00000.09102.92026.6000AID1799783
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)1.59000.00022.45859.9600AID1640021
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaTissue-type plasminogen activatorHomo sapiens (human)
proteolysisTissue-type plasminogen activatorHomo sapiens (human)
blood coagulationTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
protein modification processTissue-type plasminogen activatorHomo sapiens (human)
fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of proteolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
prevention of polyspermyTissue-type plasminogen activatorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionTissue-type plasminogen activatorHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTissue-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationTissue-type plasminogen activatorHomo sapiens (human)
angiogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
regulation of signaling receptor activityPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of plasminogen activationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of endopeptidase activityPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of smooth muscle cell migrationPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of blood coagulationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of blood coagulationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of cell migrationPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of interleukin-8 productionPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of leukotriene production involved in inflammatory responsePlasminogen activator inhibitor 1Homo sapiens (human)
fibrinolysisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of angiogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of receptor-mediated endocytosisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of inflammatory responsePlasminogen activator inhibitor 1Homo sapiens (human)
defense response to Gram-negative bacteriumPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of fibrinolysisPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of vascular wound healingPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of wound healingPlasminogen activator inhibitor 1Homo sapiens (human)
cellular response to lipopolysaccharidePlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of monocyte chemotaxisPlasminogen activator inhibitor 1Homo sapiens (human)
replicative senescencePlasminogen activator inhibitor 1Homo sapiens (human)
dentinogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of odontoblast differentiationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of smooth muscle cell-matrix adhesionPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processPlasminogen activator inhibitor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase activityTissue-type plasminogen activatorHomo sapiens (human)
signaling receptor bindingTissue-type plasminogen activatorHomo sapiens (human)
protein bindingTissue-type plasminogen activatorHomo sapiens (human)
phosphoprotein bindingTissue-type plasminogen activatorHomo sapiens (human)
protease bindingPlasminogen activator inhibitor 1Homo sapiens (human)
serine-type endopeptidase inhibitor activityPlasminogen activator inhibitor 1Homo sapiens (human)
signaling receptor bindingPlasminogen activator inhibitor 1Homo sapiens (human)
protein bindingPlasminogen activator inhibitor 1Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
collagen-containing extracellular matrixTissue-type plasminogen activatorHomo sapiens (human)
extracellular regionTissue-type plasminogen activatorHomo sapiens (human)
cytoplasmTissue-type plasminogen activatorHomo sapiens (human)
cell surfaceTissue-type plasminogen activatorHomo sapiens (human)
secretory granuleTissue-type plasminogen activatorHomo sapiens (human)
apical part of cellTissue-type plasminogen activatorHomo sapiens (human)
extracellular exosomeTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexTissue-type plasminogen activatorHomo sapiens (human)
Schaffer collateral - CA1 synapseTissue-type plasminogen activatorHomo sapiens (human)
glutamatergic synapseTissue-type plasminogen activatorHomo sapiens (human)
extracellular spaceTissue-type plasminogen activatorHomo sapiens (human)
collagen-containing extracellular matrixPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular regionPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular spacePlasminogen activator inhibitor 1Homo sapiens (human)
plasma membranePlasminogen activator inhibitor 1Homo sapiens (human)
platelet alpha granule lumenPlasminogen activator inhibitor 1Homo sapiens (human)
collagen-containing extracellular matrixPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular exosomePlasminogen activator inhibitor 1Homo sapiens (human)
serine protease inhibitor complexPlasminogen activator inhibitor 1Homo sapiens (human)
peptidase inhibitor complexPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular spacePlasminogen activator inhibitor 1Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID363329Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID102410Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 10 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID102411Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 3 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID102409Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 1 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID363328Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1799783Enzymatic Assay from Article 10.1074/jbc.M109.067967: \\Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.\\2010The Journal of biological chemistry, Mar-12, Volume: 285, Issue:11
Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.20 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index70.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]